News & Analysis on Biopharmaceutical Manufacturing & Bioprocessing Tech
By Ben Hargreaves & Maggie Lynch
- Last updated on
Following BMS’ $74bn (€65.2bn) decision to acquire Celgene, the company revealed how its new leadership lineup would look through the integration of the biotech.
Giovanni Caforio will remain CEO, working with Celgene’s Rupert Vassey, who will lead BMS’ research and early development division, Nadim Ahmed, who will lead the haematology division, and David Elkins, who will become CFO.
Elkins will replace Charles Bancroft, who will take on the role of executive lead for integration, before retiring during 2020 – ending his 35 years at the company.
In addition, Samit Hirawat will join BMS as CMO, arriving at the company from Novartis, where he was head of oncology development.
BMS’ current CSO, Tom Lynch, will remain in his position until October 1, 2019, at which point he will leave to “pursue opportunities in healthcare.”
“I’m looking forward to working with this leadership team as we combine the strengths of BMS and Celgene to enhance the value of our marketed portfolio, deliver six significant new product launches and realise the full potential of our deep and broad pipeline,” said Caforio.
According to BMS, the newly merged company will base the leadership roles around two core areas, research and early development and global drug development.